Press Releases ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Delayed Nasdaq Other stock markets 01:03:43 2024-04-30 pm EDT			5-day change	1st Jan Change
1.95 ^USD	-1.02%		-3.47%	-1.52%

Mar. 14	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
Mar. 13	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting	Apr. 23	AQ
ProQR Therapeutics N : AGM 2024 Notice and Agenda	Apr. 23	PU
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English redline	Apr. 23	PU
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English clean	Apr. 23	PU
ProQR Therapeutics N : AGM 2024 Board Compensation Policy one-tier Board	Apr. 23	PU
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board redline	Apr. 23	PU
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board clean	Apr. 23	PU
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024	Apr. 23	GL
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting	Apr. 22	GL
ProQR Therapeutics N : AGM 2024 Explanatory Notes	Apr. 22	PU
ProQR Therapeutics N : AGM 2024 POA Registered Shareholders	Apr. 22	PU
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio	Apr. 22	AQ
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio	Apr. 19	GL
ProQR Announces Year End 2023 Operating and Financial Results	Mar. 13	GL
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing	Feb. 15	GL
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024	Jan. 19	GL
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration	Jan. 05	GL
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration	Jan. 05	AQ
ProQR Therapeutics Announces Transaction Completed for Thea to Acquire Sepofarsen and Ultevursen Ophthalmic Assets	Dec. 11	AQ
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets	Dec. 08	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Press Releases

Filters